China Universal Asset Management Company’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-21,225
Closed -$843K 521
2026
Q1
$843K Buy
21,225
+5,504
+35% +$141K 0.06% 212
2025
Q4
$393K Sell
15,721
-1,095
-7% -$27.7K 0.03% 281
2025
Q3
$408K Sell
16,816
-2,365
-12% -$42K 0.03% 266
2025
Q2
$252K Buy
19,181
+870
+5% +$11K 0.02% 291
2025
Q1
$263K Sell
18,311
-598
-3% -$9.79K 0.02% 291
2024
Q4
$317K Buy
18,909
+5,316
+39% +$88.1K 0.03% 293
2024
Q3
$217K Buy
13,593
+6,785
+100% +$83.1K 0.02% 294
2024
Q2
$61.5K Sell
6,808
-4,009
-37% -$38K 0.01% 344
2024
Q1
$122K Buy
10,817
+4,423
+69% +$41.9K 0.02% 350
2023
Q4
$50.9K Buy
6,394
+5,037
+371% +$33.8K 0.01% 369
2023
Q3
$8.78K Buy
1,357
+666
+96% +$4.56K ﹤0.01% 355
2023
Q2
$4.28K Sell
691
-21
-3% -$100 ﹤0.01% 384
2023
Q1
$2.74K Buy
712
+179
+34% +$655 ﹤0.01% 422
2022
Q4
$1.65K Buy
533
+52
+11% +$193 ﹤0.01% 383
2022
Q3
$2K Buy
+481
New +$2.2K ﹤0.01% 346

China Universal Asset Management Company's CNTA Position: Q2 2026 in Review

China Universal Asset Management Company sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 21,225 shares — an estimated $843K sold.

China Universal Asset Management Company first reported a position in CNTA in Q3 2022 and held it in 15 quarters. The position peaked at $843K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • China Universal Asset Management Company reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • China Universal Asset Management Company sold 21,225 Centessa Pharmaceuticals shares in Q2 2026, an estimated $843K.
  • China Universal Asset Management Company first reported a position in Centessa Pharmaceuticals in Q3 2022 and held it in 15 quarters.
  • China Universal Asset Management Company's Centessa Pharmaceuticals position peaked at $843K in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.